報價延遲最少15分鐘:2025/07/18 17:49 EDT
盤後時段
|
||||
|
1.1 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.1
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.29/--
|
|
企業價值
36.57M
|
| 資產負債 |
|
每股賬面淨值
-3.70
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 17:49 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Profusa Inc is a digital health technology company based in Emeryville, CA, that has developed a real-time, consumer-friendly platform that is designed to measure an individual's biochemistry, be easy to use, be cost-effective, and providethe necessary data to manage chronic disease and health and wellness decisions to improve health outcomes for a large population of potential users. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. |
